This trial is a two arm, multicentre parallel group, randomised controlled, open label trial comparing intravenous levetiracetam to intravenous phenytoin for the treatment of convulsive status epilepticus (CSE) in children, young people and young adults.
The trial will run in emergency depatments in NHS secondary and tertiary hospitals in the UK, a total of 308 participants will be recruited and total study duration for each participant will be 24 hours. The Consent study will run alongside EcLiPSE and will involve parents who have been approached about the study and EcLiPSE recruiters. The study will examine approaches to recruitment and deferred consent and explore the views of parents with the aim of identifying recruitment and consent issues and potential solutions to inform EcLiPSE recruiter training materials.
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax